Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

@article{Detke2002Duloxetine6M,
  title={Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.},
  author={Michael J. Detke and Yili Lu and David John Goldstein and J. R. Hayes and Mark A. Demitrack},
  journal={The Journal of clinical psychiatry},
  year={2002},
  volume={63 4},
  pages={308-15}
}
BACKGROUND Despite treatment advances, major depressive disorder (MDD) is still a significant cause of morbidity and mortality. Current therapies frequently fall short of providing full remission. In addition, physical symptoms are commonly seen in MDD patients, increasing overall morbidity and health care utilization. Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 117 extracted citations

The role of duloxetine in the treatment of anxiety disorders

Neuropsychiatric disease and treatment • 2008
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…